ang - 3777治疗后肾功能改善高危患者肾移植术后移植肾功能延迟恢复。

文章的细节

引用

复制到剪贴板

布朗伯格JS、堰先生Gaber AO,布朗BJ, Yamin妈,戈德堡ID,梅恩TJ,库珀M

ang - 3777治疗后肾功能改善高危患者肾移植术后移植肾功能延迟恢复。

移植。2020年4月6日。doi: 10.1097 / TP.0000000000003255。

PubMed ID

32265417 (在PubMed

]

文摘

背景:20到50%的肾移植患者急性肾损伤的经验导致移植肾功能延迟恢复(DGF)。ang - 3777是一个结合c-MET受体HGF模仿。在动物模型中,ang - 3777细胞凋亡减少,增加扩散,促进器官修复和功能。方法:本研究是一项随机,双盲,安慰剂对照,第二阶段试验的肾移植患者< 50 cc / h尿量连续八小时在第一个24小时post-transplantation;和/或降低肌酐比值< 30% pretransplantation post-transplantation 24小时。受试者被随机2:1 - 3,每日一次静脉输液ang - 3777 2毫克/公斤(n = 19)或安慰剂(n = 9)。主要终点:时间在天实现> / = 1200 cc尿/ 24小时。结果:患者ang - 3777更有可能达到1200 cc的主要终点24小时尿28天post-transplantation (78.9% vs 44.4%安慰剂;生存率较:x = 2.799, p = 0.09)。与安慰剂相比,病人在ang - 3777臂的尿量; lower SCr; greater reduction in C-reactive protein (CRP) and neutrophil gelatinase-associated lipocalin (NGAL); fewer dialysis sessions and shorter duration of dialysis; fewer hospital days; significantly less graft failure; and higher eGFR. Adverse events occurred in a similar percentage of subjects in both arms. Events per subject were twice as high in the placebo arm. CONCLUSIONS: There was an efficacy signal for improved renal function in subjects treated with ANG-3777 relative to placebo, with a good safety profile.

DrugBank数据引用了这篇文章

药物

Terevalefim